# Poolbeg Pharma agrees terms to develop an oral vaccine delivery platform

- Link: https://www.directorstalkinterviews.com/poolbeg-pharma-agrees-terms-to-develop-an-oral-vaccine-delivery-platform/4121039043
- Published: 2021-12-16T07:19:26+00:00
- Author: Giles

**Poolbeg Pharma plc** ([LON:POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l))
a clinical stage infectious disease pharmaceutical company with a capital light 
clinical model, has signed a binding term sheet, encompassing all commercial terms,
with AnaBio Technologies (AnaBio), with a full licence and collaboration agreement
to follow.

The partnership allows Poolbeg exclusive access to AnaBio’s microencapsulation and
nanoencapsulation technologies, IP and expertise for oral vaccine applications. 
Poolbeg will utilise this technology in conjunction with its own expertise in infectious
diseases, vaccine development and its associated technologies to develop an oral
vaccine delivery platform. Poolbeg will also investigate using its proprietary Vaccine
Discovery Platform in conjunction with this jointly developed oral vaccine delivery
platform.

Oral vaccines for diseases such as polio have been used successfully for decades
by delivering antigens to specific areas of the gut with the objective of stimulating‘
mucosal immunity’, which prevents pathogens infecting the body. Oral vaccines offer
an efficient method of administration, reducing significant challenges for distribution
and administration addressing the gaps in supplying the global community as well
as addressing needle-phobia.

Microencapsulation is key to delivering drugs to the gut and results in prolonged
absorption profiles. Microencapsulation also helps to ensure the right dose of a
product is absorbed by the body. Preliminary data has shown that AnaBio’s platform
may be combined with dual nanotechnology to create a two-step delivery process with
enhanced uptake to specific cells. This technology platform can be used to encapsulate
a wide range of drugs including molecules such as proteins, peptides, DNA and RNA.
As a result of the pandemic, mRNA vaccines have been one of the standout success
stories in the fight against COVID-19.

> **Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said: **“As we have seen in 
> the COVID-19 pandemic, the success of global vaccination drives is dependent on
> the effective uptake of vaccines. Oral vaccines are highly attractive due to their
> improved stability profiles, ease of administration, generation of mucosal immunity
> and being preferable to needle-phobic patients.
> “The pharma sector is increasingly recognising that oral vaccines can act as standalone
> regimens or as boosters to injected vaccines which can struggle to generate mucosal
> immunity. By working with the experts at AnaBio and accessing its advanced micro
> and nano encapsulation technology, this places Poolbeg in a prime position to 
> develop products for the oral vaccine market with vaccines for enteric (gut) and
> respiratory pathogens.”

> **Aidan Fitzsimons, PhD, CEO of, AnaBio Technologies, said: **“The global pandemic
> has led to a major acceleration in vaccine development based on a deeper understanding
> of how to create and maintain immunity to disease; including the importance of
> mucosal immunity in addition to blood immunity.  We believe that our patented 
> microencapsulation technology designed to deliver intact active pharmaceutical
> ingredients (APIs) to specific sites within the body, combined with Poolbeg’s 
> innate knowledge of viruses, could enable us together to create effective oral
> vaccines and make a significant impact on the vaccine market.”

Share on:
